Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi (SNY) announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is a CD20-directed bispecific myeloid cell engager designed to induce deep B-cell depletion. Dren Bio is currently evaluating the drug in two ongoing early-stage studies — B-cell non-Hodgkin lymphoma and autoimmune diseases.Sanofi believes that DR-0201 has the potential to reset the immune system, which can lead ...